Path2Integrity: MORE THAN 200 STUDENTS FROM ACROSS EUROPE TACKLE FAKE NEWS
A Europe-wide workshop on Fake News with Rainer Wieland, Vice-President of the European Parliament aims to identify reliable information and encourage responsible action.
March 31, 2021 – COBURG, MADRID - How can you distinguish reliable from false information? How can you recognise and combat fake news? What characterizes serious and responsible research? These were some of the questions tackled by more than 200 European high school students from Germany, Italy, Kosovo, Serbia, and Spain as part of the Europe-wide project Path2Integrity.
The students came together in a workshop featuring the participation of Rainer Wieland, Vice-President of the European Parliament. It was organised by Prof. Dr Priess-Buchheit, Coburg University of Applied Sciences, and Katharina Miller, a lawyer from Madrid, to help them learn more about fake news and reliable information.
“It is critically important that students learn to assess the quality and veracity of information to which they may be exposed,” said Priess-Buchheit. “This is especially important today as people and societies grapple with issues related to Covid, and science struggles to be heard and trusted in a sea of voices.”
In this international workshop employing innovative learning methods, the students encountered and discussed different fake news challenges and examined concrete situations in which fake news had become a problem. Through reflection and active joint actions, they were able to address these issues. In doing so, the students learned how crucial responsible research is to obtain reliable information.
Students shared what they had learned in an intensive discussion with Rainer Wieland. Wieland, an experienced European politician, emphasised the central value of media freedom and pluralism. Both are essential pillars of modern democracy. "To support these pillars, we together must fight all forms of fake news", he said.
For more information visit: www.path2integrity.eu
Rebecca Fischer, M.A.
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
ARD Presse: CIVIS MEDIA PRIZE 2021 - 23 productions nominated, 5 podcasts for the public vote15.4.2021 11:22:26 CEST | Press release
(Cologne, Germany): CIVIS Media Prize 2021 – The 23 nominees of what is Europe's most important media prize when it comes to integration and cultural diversity have been selected: Candidates for the CIVIS Media Prize include entries from ARTE, Bayerischer Rundfunk, Filmakademie Baden-Württemberg, FYEO, HBO, Mitteldeutscher Rundfunk, Norddeutscher Rundfunk, Österreichischer Rundfunk, ProSieben, Radio Bremen, Saarländischer Rundfunk, Schweizer Radio und Fernsehen, Südwestrundfunk, Westdeutscher Rundfunk and ZDF. The productions deal with highly topical issues such as flight, racism, right-wing extremism and antisemitism in many different ways; however, they also cover strategies against hate and violence as well as strategies for the peaceful coexistence of people with diverse geographical and cultural origins. Nearly 800 productions from television, radio and the Internet were submitted for the CIVIS Competition 2021. They came from 20 EU states and Switzerland. The complete list of nom
Grünenthal Group: Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee12.4.2021 11:47:13 CEST | Press release
With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. (Aachen, Germany) –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and function
Fluxergy, Inc. Receives CE-IVD Marking for a One-Hour COVID-19 RT-PCR Test and Positions for European Market Entry12.4.2021 09:00:00 CEST | Press release
IRVINE, CA., April 12, 2021 – Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy’s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval. Fluxergy’s platform is an automated, sample-to-answer testing platform with multimodal capability allowing for a variety of assay types, such as molecular, immunochemistry, chemistry, and cytometry assays, to be run simultaneously on the same cartridge. This will give users the ability to run unique Point-of-Care (PoC) panels with the potential ability to do built-in reflex testing, among other capabilities. Potential environments for rapid testing applications include emergency ro
Avonisys AG: Avonisys AG wins patent litigation case against Synova SA7.4.2021 15:36:04 CEST | Press release
Swiss Federal Patent Court rules in favour of Avonisys AG in all relevant aspects and convicts Synova SA under the unfair competition act:
Grunenthal Group: Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks7.4.2021 11:39:12 CEST | Press release
• Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry • Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies like Pfizer and Roche (Aachen, Germany): Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector. “The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” said Gabriel Baertschi, CEO Grünenthal. “While we are proud to
DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life6.4.2021 09:15:56 CEST | Press release
The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible care solutions, to link to specialized advisors, doctors and digital solutions in obesity care, and by supporting them with the testimonials of peers who took action to better manage their health, all within one digital location. The program launches today in Germany with the intention to expand across other European markets.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom